Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A modular, multi-arm, first-in-human trial to evaluate the safety and tolerability of MDX-124 alone and in combination with anti-cancer treatments, in participants with locally advanced, unresectable or metastatic solid malignancies

Next Previous
Trial Profile

A modular, multi-arm, first-in-human trial to evaluate the safety and tolerability of MDX-124 alone and in combination with anti-cancer treatments, in participants with locally advanced, unresectable or metastatic solid malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MDX 124 (Primary) ; Gemcitabine; Paclitaxel
  • Indications Bladder cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Liver cancer; Lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; First in man
  • Acronyms ATTAINMENT
  • Sponsors Medannex

Most Recent Events

  • 04 Jun 2024 According to trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology, Cohorts at 1, 2.5 and 5 mg/kg have been completed without DLT and enrollment to cohort 4 (10 mg/kg) began in January 2024.
  • 04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
  • 01 Dec 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top